227 related articles for article (PubMed ID: 18360656)
1. Update on the appropriate use of linezolid in clinical practice.
Manfredi R
Ther Clin Risk Manag; 2006 Dec; 2(4):455-64. PubMed ID: 18360656
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Manfredi R
Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
[TBL] [Abstract][Full Text] [Related]
3. A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting.
Manfredi R
Mini Rev Med Chem; 2005 Dec; 5(12):1075-81. PubMed ID: 16375753
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
5. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
6. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
Manfredi R; Sabbatani S
Braz J Infect Dis; 2010; 14(1):96-108. PubMed ID: 20428664
[TBL] [Abstract][Full Text] [Related]
7. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
8. New antimicrobial agents as therapy for resistant gram-positive cocci.
Lentino JR; Narita M; Yu VL
Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
Reis AO; Cordeiro JC; Machado AM; Sader HS
Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
[TBL] [Abstract][Full Text] [Related]
10. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
Klastersky J
Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
13. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.
Shariati A; Dadashi M; Chegini Z; van Belkum A; Mirzaii M; Khoramrooz SS; Darban-Sarokhalil D
Antimicrob Resist Infect Control; 2020 Apr; 9(1):56. PubMed ID: 32321574
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
[TBL] [Abstract][Full Text] [Related]
15. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance among gram-positive organisms in the intensive care unit.
Clark NM; Hershberger E; Zervosc MJ; Lynch JP
Curr Opin Crit Care; 2003 Oct; 9(5):403-12. PubMed ID: 14508154
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
19. The need for new therapeutic agents: what is the pipeline?
Shah PM
Clin Microbiol Infect; 2005 May; 11 Suppl 3():36-42. PubMed ID: 15900655
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
